Dr. Olopade on Racial Disparities in Breast Cancer Outcomes

Video

Olufunmilayo Falusi Olopade, MD, FACP, discusses racial disparities in breast cancer outcomes.

Olufunmilayo Falusi Olopade, MD, FACP, director of the Center for Clinical Cancer Genetics, director of the Center for Global Health, associate dean for Global Health, and the Walter L. Palmer Distinguished Service Professor of Medicine and Human Genetics at the University of Chicago Medicine, discusses racial disparities in breast cancer outcomes.

Black women have the highest risk of dying from breast cancer on a global scale, according to Olopade, who was recognized as a 2020 Giant of Cancer Care® for Prevention and Genetics. When examining the reasons for these disparities, social determinants are considered to be one of the most notable contributors, Olopade says.

Although financial disparities are often cited as the cause of these disparities, Olopade notes that the COVID-19 pandemic stands as a lesson that impoverished patients shouldn't need to die in a wealthy country such as the United States. Systemic racism and barriers have segregated a large proportion of patients and prevented clinical research from focusing on populations of color, Olopade explains.

As more individuals immigrate to the United States, the population has become more diverse than ever before. Despite this, clinical trials, interventions, and publications have predominantly focused on White patients of European ancestry, Olopade concludes.

Related Videos
Video 5 - "AE Management with CDK4/6 Inhibitors: Strategies for Treatment Continuity and Optimal Patient Outcomes"
Rita Nanda, MD
Siddartha Yadav, MD, FACP
Nan Chen, MD
Video 4 - "The Evolving Treatment Landscape with CDK4/6 Inhibitors in Early HR+/HER2- Breast Cancer"
Margaret E. Gatti-Mays, MD, MPH, FACP, of The Ohio State University Comprehensive Cancer Center
Ko Un “Clara” Park, MD
Erin Frances Cobain, MD
Video 3 - "5-Year Data from the MonarchE Trial Investigating Abemaciclib in HR+, HER2- High-Risk, Early Breast Cancer"
Pasi A. Jänne, MD, PhD, discusses an exploratory analysis from the FLAURA2 trial of osimertinib plus chemotherapy in treatment-naive, EGFR-mutant NSCLC.